This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
NCT07587658
Summary
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days). The study is looking at another research question: • What side effects may happen from taking the study drug
Eligibility
Key Inclusion Criteria: 1. Has a clinical diagnosis of COPD prior to randomization, as defined in the protocol 2. Hospitalized or admitted to the ED \>24 hours (from time of first admission or presentation to the ED) for acute exacerbation of COPD as primary diagnosis according to the principal investigator and exacerbation is managed by Systemic Corticosteroids (SCS) ± antibiotics and other appropriate treatments as per SOC 3. Elevated blood eosinophil counts during the current exacerbation, as defined in the protocol. The exacerbation event starts from the day Systemic Corticosteroids (SCS) ± antibiotics are administered continuously up to the day they presented to ED/hospital Key Exclusion Criteria: 1. Clinical evidence of pneumonia as the primary cause of admission in the investigator's opinion or acquired during hospital stay 2. Complicating pulmonary conditions during the 8 weeks prior to randomization which may confound treatment assessments, as defined in the protocol 3. Clinically significant pulmonary diseases other than COPD which may impair lung function and interfere with treatment assessments 4. Participants with clinically significant α-1 anti-trypsin deficiency which may impair lung function and interfere with treatment assessments 5. Cardiac-related comorbidity, as defined in the protocol 6. Treatment with invasive mechanical ventilation in-hospital during the index event, as defined in the protocol 7. Any biologic therapy or biologic Investigational Medicinal Product (IMP) to treat type 2 inflammatory diseases within 6 months prior to the screening visit or 5 half-lives, whichever is longer, as defined in the protocol NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Conditions2
Interventions1
Locations1 site
Find trials near these locations
Related trials
- DETACT sEvere asThmAtiC paTients - a Pilot Study — Medical University of Vienna
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer — Centre hospitalier de l'Université de Montréal (CHUM)
- Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions — Sanofi
- The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis — Sanofi
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — Sanofi
- Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping — University of California, San Diego
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC — Icahn School of Medicine at Mount Sinai
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases — Dan Feng
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07587658